Company Reports - Research and Markets - RSS Feed

Ethicon Medical Device Company Intelligence Report

press@researchandmarkets.com — Wed, 16 Sep 2009 15:17:15 GMT

Ohio, US-based Ethicon Endo-Surgery Inc (EES) develops and markets advanced medical devices for minimally-invasive and open surgical procedures The company focuses on procedure-enabling devices for the interventional diagnosis and treatment of conditions in general and bariatric surgery, as well as...

Danaher Medical Device Company Intelligence Report

press@researchandmarkets.com — Thu, 18 Jun 2009 13:50:32 GMT

Danaher Corporation designs, manufactures and markets medical, professional, industrial, commercial and consumer products and services, which are typically characterised by brand names in four business segments: Medical Technologies, Professional Instrumentation, Industrial Technologies and Tools &...

The Immune/Inflammatory Pipeline: A Strategic Review

press@researchandmarkets.com — Tue, 09 Jun 2009 11:19:06 GMT

The current immune/inflammatory pipeline is over 375 drugs strong, with approximately 250 companies involved in these agents’ development Yet, despite this robust pipeline size, Decision Resources analysts do not believe that any one agent in development will significantly alter the way physicians...

Omega-3 Nutrients - An Emerging Product Additive Among U.S. General Consumers

press@researchandmarkets.com — Fri, 12 Sep 2008 08:39:44 GMT

This research service analyzes the consumers' choice of omega-3 nutrient products It looks into various aspects such as consumer awareness, consumption patterns and purchase intentions of consumers...

Philips Healthcare Medical Device Company Intelligence Report

press@researchandmarkets.com — Thu, 24 Jul 2008 10:44:42 GMT

Headquartered in Best, the Netherlands, and Andover, Massachusetts, the US, Philips Healthcare is part of the multinational electronics giant, Royal Philips Electronics Group At the beginning of 2008, Philips had realigned its business activities into three separate ‘sectors’ – Healthcare, Lighting...

Scrip R&D Databook 2006

press@researchandmarkets.com — Mon, 07 Jan 2008 14:53:22 GMT

Scrip R&D Databook 2006 allows users to identify important trends within pharmaceutical R&D and benchmark their own performance. Beginning with an industry overview of R&D costs, investment levels and staffing levels, the report will then provide a comprehensive analysis of R&D trends by therapeutics class, biotechnology products, and development status.

The report will review the R&D profiles of selected leading companies. Also the inclusion of data from PharmaPredict will allow users to compare the R&D success rates of drugs with different therapeutic activities or from different companies. It will also provide an accurate estimate of how long a drug will take to reach the market.

This report will enable you to:
- Benchmark against industry performance
- Evaluate product investment potential
- Predict how long it will take your product to reach the market
- Compare therapeutic products across companies
- Get ahead of R&D trends, instead of spending time and resources in research

The Pharmaceutical R&D Databook is intended as a strategic reference guide to the important trends in pharmaceutical R&D, as well as providing the means to benchmark your company’s performance. From an examination of global R&D investment and productivity, to a breakdown of R&D trends in every major therapeutic class, the Databook provides a comprehensive review of the current R&D environment and puts it into context with an historical analysis.

Chapters 1 and 2 of the Databook look at the trends in R&D expenditure in the major markets, changes in employment patterns and productivity levels in relation to pharmaceutical sales. The US remains the powerhouse of the pharmaceutical and biotechnology industries, whilst Europe struggles to keep up. In Japan, the economic hardships of recent years have been alleviated and the Japanese pharmaceutical industry is beginning to see signs of recovery. Chapter 3 reviews the outsourcing industry and examines its role in pharmaceutical R&D.

Ch

Scrip Yearbook 2007: 23rd Edition (2 Volumes)

press@researchandmarkets.com — Mon, 07 Jan 2008 14:53:20 GMT

Scrip’s annual review of the year, Scrip Yearbook 2007 is your guide to all the key facts, events and issues of the last 12 months from across the pharmaceutical and biotechnology industries.

Collected and organised from coverage in Scrip World Pharmaceutical News, the respected source of biopharmaceutical industry news, this new updated report provides a complete and concise tool, covering all levels of the industry and recent developments.

Scrip Yearbook 2007 will help you to:
- Identify which significant mergers and acquisitions were completed
- Analyse the strategic and financial performance of your competitors
- Track the latest clinical developments and key product launches across all therapeutic areas
- Review the latest industry regulations imposed on the industry
- Gain insight from leading industry analysts and commentary from senior editors
- Keep abreast of global healthcare initiatives and market movements

Scrips Pharmaceutical Company League Tables 2007

press@researchandmarkets.com — Mon, 07 Jan 2008 14:53:20 GMT

Scrip Pharmaceutical Company League Tables 2007 allows pharma and biotech companies to benchmark their performance against their direct competitors in the industry. Rankings of performance by sales, income, investment and growth and the interactive pivot tables, mean companies can assess performance across a variety of measures.

It is an annual report that is updated to provide tables of ranking on the most important financial criteria used to evaluate company performance. Detailing the financial results for almost 200 companies in both the pharmaceutical and biotechnology industries, Scrip Pharmaceutical Company League Tables 2007 is compiled from extensive primarily research and official company records.

This report allows you to see at a glance how the world’s top pharmaceutical companies performed in 2006 in terms of total revenue, pharmaceutical sales, profitability, R&D expenditure, capital expenditure and growth within these areas.

It incorporates data on the major Western pharmaceutical and biotechnology companies for the 2006 financial year (1st January 2006-31st December 2006). It also features companies whose financial year ends on 31st March 2007, allowing the inclusion of many important companies within the Asian markets, including Astellas, Takeda, Yamanouchi, Dr Reddy. All figures have been converted from domestic currencies into US dollars and ranked in descending order to ease comparisons.

At over 250 pages and containing no less than 30 tables, the League Tables is the perfect way to analyse the trends and patterns within the pharmaceutical industry.

Features
- Analysis of the financial results of the major pharma and biotech companies worldwide for 2006, including Japanese companies and many private companies
- Rankings of industry players by sales, revenue and R&D investment
- Excel pivot tables to allow you to perform your own analysis over a five-year period.

This new, updated annual report will allow you to:
- Benchmark your performan

Scrip Yearbook 2008: 24th Edition

press@researchandmarkets.com — Mon, 07 Jan 2008 14:53:17 GMT

Scrip’s annual review of the year, Scrip Yearbook 2008 is your guide to all the key facts, events and issues of the last 12 months from across the pharmaceutical and biotechnology industries.

Collected and organised from coverage in Scrip World Pharmaceutical News, the respected source of biopharmaceutical industry news, this new updated report provides a complete and concise tool, covering all levels of the industry and recent developments.

Scrip Yearbook 2008 will help you to:
- Identify which significant mergers and acquisitions were completed
- Analyse the strategic and financial performance of your competitors
- Track the latest clinical developments and key product launches across all therapeutic areas
- Review the latest industry regulations imposed on the industry
- Gain insight from leading industry analysts and commentary from senior editors
- Keep abreast of global healthcare initiatives and market movements

2007 will, unhappily, be remembered as the year that counterfeit and contaminated medicines finally made their way into the supply chains of developed nations. As consumers in the US, UK and elsewhere in the west continued to seek access to innovative prescription medicines which they believed were being denied them by their prescribers, governments or economic forces, industry leaders warned that the illegal trade, which has already cost countless lives in developing nations, would be only too ready to exploit the new opportunities now presenting in the developed world.

Even as US Food and Drug Administration (FDA) commissioner Andrew von Eschenbach cautioned repeatedly that the agency could not guarantee the efficacy or safety of imports - often obtained over the Internet and without the need for a prescription - US Members of Congress continued their battle to legalise importation of prescription drugs from Canada and elsewhere, urged on by seniors and other consumer groups. Then the warnings became reality, when dangerously substandard

Clinicas Guide to Early-Stage Medtech Companies

press@researchandmarkets.com — Mon, 07 Jan 2008 14:53:17 GMT

This report features detailed profiles of venture backed start-ups and fast-growing companies from the US and Europe that are developing technologies for improving patient healthcare.

Whether you are a venture capitalist looking for investment opportunities, a large corporation seeking technology acquisitions, or even a start-up company wanting a clearer view of the competitive landscape, this guide is an invaluable tool.

This report will help you to:
- Review the next generation technologies that are currently being developed
- Monitor new competitors in your area
- Identify potential investment and partnering opportunities
- Assess growth areas into which other investors are putting their money and plan your own investment targets.

Clinicas Medical Device and Diagnostic Company League Tables 2006

press@researchandmarkets.com — Mon, 07 Jan 2008 14:53:16 GMT

This report is a comprehensive financial analysis of the global medical technology industry. The top 200 medical technology companies are ranked according to a number of financial criteria, including sales, sales growth, R&D spend, profit and margin.

It also ranks each companys position in the main medical technology sub-sectors, including IVDs, cardiovascular, orthopaedics, electromedical, ophthalmology, neurology and more.

This new report will allow you to:
- Benchmark your companys position against your competitors and in the market as a whole and in key product sectors
- Identify potential new markets for your products where there are relatively few competitors
- Analyse competitors and spot potential weaknesses in their financial performance
- Spot investment opportunities, acquisitions or partners
- Assist your understanding of the medtech market and its players for business plans and presentations.

Ipsen: PharmaVitae Profile

press@researchandmarkets.com — Tue, 27 Mar 2007 14:26:25 GMT

This analysis examines the historical and forecast performance for Ipsen in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to order your copy:
Benchmark Ipsens performance against key rivals in the ethical pharmaceutical sector. Determine how Ipsen will perform over the period 2006-11 having recently become a publicly run company Assess Ipsens biologic capabilities, which will play a key role in the companys sales growth performance out to 2011

Solvay: PharmaVitae Profile

press@researchandmarkets.com — Tue, 27 Mar 2007 14:26:24 GMT

This analysis examines the historical and forecast performance for Solvay in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to order your copy:
Benchmark Solvays performance against key rivals in the ethical pharmaceutical sector See how the launch of bifeprunox will drive Solvays growth to 2011, offsetting the decline of many of the companys currently marketed products Evaluate Solvays progress in integrating Fournier and the prospects of its key dyslipidemia product, fenofibrate

Servier: PharmaVitae Profile

press@researchandmarkets.com — Fri, 09 Mar 2007 10:48:17 GMT

This analysis examines the historical and forecast performance for Servier in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to order your copy:
Benchmark Serviers performance against key rivals in the ethical pharmaceutical sector Evaluate Serviers cardiovascular-centric therapeutic focus as the company seeks to record robust sales growth over the period 2005-11 Assess how Servier will continue to outperform its peers, due to the companys insulation from generic competition and core portfolio growth

Millennium: PharmaVitae Profile

press@researchandmarkets.com — Fri, 09 Mar 2007 10:48:17 GMT

This analysis examines the historical and forecast performance for Millennium in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to order your copy:
Benchmark Millennium s performance against key rivals in the ethical pharmaceutical sector Analyze how Millennium will increase its therapeutic focus on the high-growth oncology market by building on its initial success with Velcade Assess Millenniums exclusive dependence on the Velcade and Integrilin product franchises to drive sales growth over the period 2005-11

Strategic Company Profile - Coloplast

press@researchandmarkets.com — Tue, 21 Nov 2006 15:41:51 GMT

Value to Participants in the Continence and Ostomy Care Markets

Coloplast is a major participant in the continence and ostomy markets and has a strong presence in the breast and wound care markets as well. Frost & Sullivans research provides an in-depth view of Coloplasts core competencies. It analyzes Coloplasts current strengths in the continence and ostomy markets and also looks into its future prospects of strengthening its presence in these sectors.

Includes Financial Profile along with a Product Profile

The study outlines the products in each of the categories and looks at Coloplasts role in the individual markets. It also looks at the financials for each of the segments, thus providing a complete understanding of Coloplast as a company. The product profile gives a snapshot of the products Coloplast has in the market and the brands they are promoted under. Also included is the companys financial profile - revenue history over the last five years - along with other key ratios and figures.

Investment Analyst Perspective Provided

An investment analysts perspective of Coloplast is included in the study. This gives an authentic in-depth view of the financial profile of Coloplast. An equity research analyst who has been covering the medical devices sector and Coloplast, in particular was interviewed to gain his perspective on the industry and the company.

Abbott Laboratories BusIntell Report

press@researchandmarkets.com — Wed, 19 Jul 2006 13:46:41 GMT

Abbott Laboratories (Abbott) has emerged as one of the world's top health care companies Today, Abbott discovers, develops, manufactures, and markets products and services that span the continuum of care - from prevention and diagnosis, to treatment and cure Abbott casts a keen focus on therapeutic...